The news: Eli Lilly is suing four telehealth companies over allegedly marketing and selling compounded versions of Lilly’s blockbuster GLP-1 drugs Zepbound and Mounjaro. Lawsuits have been filed against Mochi Health, Fella Health, Willow Health and Henry Meds.

Zooming out: The FDA states that compounded forms of tirzepatide that are exact copies of tirzepatide cannot be sold anymore, now that the drug is no longer in short supply. Some companies think they can take advantage of a regulatory loophole that would allow them to make personalized doses of GLP-1s that aren’t exact copies.

Lilly has taken plenty of legal action against pharmacies, clinics, med spas, and others over advertising and selling compounded versions of its GLP-1s.